Enhertu 100 mg Powder for IV Infusion is a groundbreaking anti-cancer treatment developed by Daiichi-Sankyo, containing Trastuzumab Deruxtecan. Enhertu 100 mg is a next-generation antibody-drug conjugate (ADC) specifically designed to target HER2-positive cancers. Enhertu 100 mg Trastuzumab Deruxtecan is widely prescribed for patients battling advanced or metastatic breast cancer, gastric cancer, and other HER2-expressing tumors.
Enhertu 100 mg Powder for IV Infusion works by combining trastuzumab, a monoclonal antibody targeting HER2 receptors, with a potent chemotherapy agent (deruxtecan). This unique mechanism allows Enhertu 100 mg to selectively bind to HER2-positive cancer cells and deliver chemotherapy directly into the tumor, minimizing damage to healthy cells.
🔥 Key Benefits & Uses of Enhertu 100 mg Trastuzumab Deruxtecan:
- Advanced Breast Cancer: Enhertu 100 mg Trastuzumab Deruxtecan is primarily used to treat HER2-positive metastatic breast cancer in patients who have received prior anti-HER2 therapies.
- Gastric Cancer: Enhertu 100 mg is also approved for HER2-positive advanced gastric cancer after previous treatment regimens.
- HER2-Low Breast Cancer: Enhertu 100 mg Trastuzumab Deruxtecan is a pioneering option for HER2-low expressing breast cancer, expanding treatment eligibility to more patients.
- Targeted Drug Delivery: Enhertu 100 mg’s antibody-drug conjugate technology delivers chemotherapy directly to cancer cells, enhancing effectiveness while reducing systemic toxicity.
- Improved Survival Rates: Clinical trials have demonstrated that Enhertu 100 mg significantly extends progression-free survival and overall survival in HER2-positive cancer patients.
💉 How to Use Enhertu 100 mg Trastuzumab Deruxtecan:
- Administration: Enhertu 100 mg is administered as an intravenous infusion under the supervision of a healthcare professional.
- Dosage: Typically given once every three weeks, but the exact dosage and frequency depend on the patient’s weight and treatment plan.
- Monitoring: Regular medical check-ups are necessary during Enhertu 100 mg therapy to monitor for any potential side effects.
🧊 Storage Instructions:
- Store Enhertu 100 mg Powder for IV Infusion below 25°C.
- Protect Enhertu 100 mg from light and moisture.
- Keep out of reach of children.
⚠️ Potential Side Effects of Enhertu 100 mg Trastuzumab Deruxtecan:
- Nausea, vomiting, or fatigue.
- Decreased blood cell counts (neutropenia, anemia).
- Lung complications (Interstitial Lung Disease – ILD), which may require immediate medical attention.
- Hair loss, diarrhea, or loss of appetite.
🌍 Why Choose Enhertu 100 mg Trastuzumab Deruxtecan by Daiichi-Sankyo?
- Developed by Daiichi-Sankyo, a global leader in oncology treatments.
- Proven efficacy in HER2-positive and HER2-low breast cancer patients.
- Cutting-edge antibody-drug conjugate (ADC) technology.
- Positive clinical trial results, transforming the treatment landscape for HER2-expressing cancers.
✅ Real Patient Reviews:
“After trying several treatments, Enhertu 100 mg made a noticeable difference. My scans improved, and I feel hopeful for the future.” – Patient Testimonial
🔗 Official Resource:
Daiichi-Sankyo Enhertu Official Page – For comprehensive prescribing information and medical guidelines.
Değerlendirmeler
Henüz değerlendirme yapılmadı.